collection
MENU ▼
Read by QxMD icon Read
search

Project metformin

shared collection
7 papers 25 to 100 followers
By Nachiketh Soodana Prakash Medical graduate plus Masters in clinical Research
https://www.readbyqxmd.com/read/17387371/androgen-deprivation-therapy-in-the-treatment-of-advanced-prostate-cancer
#1
Mark A Perlmutter, Herbert Lepor
This article reviews the issues and controversies relevant to the treatment of advanced prostate cancer with androgen deprivation therapy. Initially, diethylstilbestrol was used for achieving androgen deprivation, but was replaced by luteinizing hormone-releasing hormone (LHRH). Adverse events associated with LHRH agonists include the flare phenomenon, hot flashes, loss of libido, erectile dysfunction, depression, muscle wasting, anemia, and osteoporosis. Intermittent therapy has been advocated to reduce morbidity of treatment...
2007: Reviews in Urology
https://www.readbyqxmd.com/read/22162475/androgen-deprivation-therapy-as-primary-treatment-for-prostate-cancer
#2
REVIEW
Dara H Cannata, Alexander Kirschenbaum, Alice C Levine
CONTEXT: Hormonal therapy has been the mainstay of treatment for advanced prostate cancer for over 70 yr. The timing and extent of androgen ablative therapy for earlier stage disease remains controversial. In addition, recent studies demonstrate that so-called "castration-resistant" tumors are still dependent on androgen receptor signaling. PATIENT AND METHODS: A 66-yr-old man presented with clinical stage T1C N+ M0 prostate cancer and received primary androgen deprivation therapy...
February 2012: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/23724747/advances-in-the-treatment-of-metastatic-prostate-cancer
#3
Simon Chowdhury, Roger Kirby
Prostate cancer is the most common cancer in men in the UK. It accounts for nearly a quarter of all male cancer diagnoses and is the second most common cause of male cancer death. Despite a large increase in prostate cancer incidence, mortality rates have remained relatively constant through improvements in survival. Most patients present with localised disease, but there are still many who present with metastatic disease. Prostate cancers are driven by androgens, such as testosterone. Androgen deprivation therapy (ADT), which is still the mainstay of systemic treatment, effectively reduces intraprostatic androgen levels resulting in reduced androgen receptor (AR) stimulation and increased apoptosis...
April 2013: Practitioner
https://www.readbyqxmd.com/read/18172860/endogenous-sex-hormones-and-the-risk-of-prostate-cancer-a-prospective-study
#4
RANDOMIZED CONTROLLED TRIAL
Jocelyn M Weiss, Wen-Yi Huang, Sabina Rinaldi, Thomas R Fears, Nilanjan Chatterjee, Ann W Hsing, E David Crawford, Gerald L Andriole, Rudolf Kaaks, Richard B Hayes
Sex steroid hormones influence prostate development and maintenance through their roles in prostate cellular proliferation, differentiation and apoptosis. Although suspected to be involved in prostate carcinogenesis, an association between circulating androgens and prostate cancer has not been clearly established in epidemiologic studies. We conducted a nested case-control study with prospectively collected samples in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, to examine associations of prostate cancer with androstenedione (Delta4-A), testosterone (T), sex hormone-binding globulin (SHBG) and 3alpha-androstanediol glucuronide (3alpha-diolG)...
May 15, 2008: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/23287698/metformin-and-prostate-cancer-reduced-development-of-castration-resistant-disease-and-prostate-cancer-mortality
#5
Daniel E Spratt, Chi Zhang, Zachary S Zumsteg, Xin Pei, Zhigang Zhang, Michael J Zelefsky
BACKGROUND: In vitro data and early clinical results suggest that metformin has desirable antineoplastic effects and has a theoretical benefit on castration-resistant prostate cancer (CRPC). OBJECTIVE: To determine whether the use of metformin would be associated with improved clinical outcomes and a reduction in the development of CRPC. DESIGN, SETTING, AND PARTICIPANTS: Data from 2901 consecutive patients (157 metformin, 162 diabetic non-metformin, and 2582 nondiabetic) with localized prostate cancer treated with external-beam radiation therapy from 1992 to 2008 were collected from a single institution in the United States...
April 2013: European Urology
https://www.readbyqxmd.com/read/23228172/abiraterone-in-metastatic-prostate-cancer-without-previous-chemotherapy
#6
RANDOMIZED CONTROLLED TRIAL
Charles J Ryan, Matthew R Smith, Johann S de Bono, Arturo Molina, Christopher J Logothetis, Paul de Souza, Karim Fizazi, Paul Mainwaring, Josep M Piulats, Siobhan Ng, Joan Carles, Peter F A Mulders, Ethan Basch, Eric J Small, Fred Saad, Dirk Schrijvers, Hendrik Van Poppel, Som D Mukherjee, Henrik Suttmann, Winald R Gerritsen, Thomas W Flaig, Daniel J George, Evan Y Yu, Eleni Efstathiou, Allan Pantuck, Eric Winquist, Celestia S Higano, Mary-Ellen Taplin, Youn Park, Thian Kheoh, Thomas Griffin, Howard I Scher, Dana E Rathkopf
BACKGROUND: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy. METHODS: In this double-blind study, we randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The coprimary end points were radiographic progression-free survival and overall survival...
January 10, 2013: New England Journal of Medicine
https://www.readbyqxmd.com/read/21421541/metformin-in-prostate-cancer-two-for-the-price-of-one
#7
REVIEW
A Clements, B Gao, S H O Yeap, M K Y Wong, S S Ali, H Gurney
BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer treatment induces a metabolic syndrome, which may contribute to non-cancer-related morbidity and mortality. Metformin may abrogate these effects. Additionally, metformin has potential antineoplastic activity in various malignancies including prostate cancer. MATERIALS AND METHODS: A literature review using PubMed with the keywords: AMPK, androgen deprivation therapy, insulin resistance, metabolic syndrome, metformin and prostate cancer was undertaken...
December 2011: Annals of Oncology: Official Journal of the European Society for Medical Oncology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"